Chen Yao, Bao ShanQing, Ding Yijie, Weng GuangDong, Zheng ShiJie, Ge ChaoLiang, Zhang ChengXin
Department of Cardiovascular Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.
Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, School of Pharmacy, Anhui Medical University, Hefei, China.
Int Immunopharmacol. 2025 May 27;156:114732. doi: 10.1016/j.intimp.2025.114732. Epub 2025 Apr 27.
Inflammation serves as a critical driver in coronary artery disease pathogenesis. Emerging clinical evidence demonstrates that low-dose colchicine therapy significantly reduces ischemic event incidence in patients with coronary heart disease while attenuating myocardial ischemia-induced inflammatory cascades. Nevertheless, the precise cardioprotective mechanisms underlying colchicine-a plant-derived anti-inflammatory agent-in limiting post-infarction cardiomyocyte injury remain incompletely elucidated. This study systematically investigates colchicine's myocardial preservation mechanisms through an integrated experimental approach.
To establish experimental models of myocardial injury, we performed permanent ligation of the left anterior descending coronary artery (LAD) in mice for in vivo studies, while HL-1 mouse atrial cardiomyocytes were treated with 0.3 mM H₂O₂ to induce oxidative stress in vitro. Following successful model validation, colchicine was administered to both systems. Comprehensive evaluations included echocardiographic assessment of cardiac function, histological examination of inflammatory infiltration and collagen deposition through H&E and Masson's trichrome staining respectively, quantitative analysis of cardiomyocyte apoptosis by flow cytometry, and Western blot detection of key signaling pathway components and pyroptosis-related proteins (including NLRP3, caspase-1, and GSDMD).
Our experimental data revealed that colchicine treatment significantly attenuated myocardial injury and fibrosis while improving cardiac function (P < 0.05). Mechanistically, colchicine administration reduced proinflammatory cytokine release (IL-1β and IL-18), decreased neutrophil infiltration, and suppressed cardiomyocyte pyroptosis. These cardioprotective effects were associated with modulation of the ESR1-PI3K-Akt-NF-κB signaling pathway (P < 0.05), suggesting a potential therapeutic mechanism for colchicine in myocardial protection.
Colchicine inhibits myocardial pyroptosis and reduces myocardial cell injury after myocardial infarction through the ESR1-PI3K-Akt-NF-κB signaling pathway.
炎症是冠状动脉疾病发病机制中的关键驱动因素。新出现的临床证据表明,低剂量秋水仙碱治疗可显著降低冠心病患者缺血事件的发生率,同时减轻心肌缺血诱导的炎症级联反应。然而,秋水仙碱(一种植物源性抗炎药)在限制心肌梗死后心肌细胞损伤方面的确切心脏保护机制仍未完全阐明。本研究通过综合实验方法系统地研究秋水仙碱的心肌保护机制。
为建立心肌损伤实验模型,我们对小鼠进行左冠状动脉前降支(LAD)永久性结扎以进行体内研究,同时用0.3 mM H₂O₂处理HL-1小鼠心房心肌细胞以在体外诱导氧化应激。成功验证模型后,对两个系统均给予秋水仙碱。综合评估包括通过超声心动图评估心脏功能,分别通过苏木精-伊红(H&E)染色和马松三色染色对炎症浸润和胶原沉积进行组织学检查,通过流式细胞术对心肌细胞凋亡进行定量分析,以及通过蛋白质免疫印迹法检测关键信号通路成分和焦亡相关蛋白(包括NLRP3、半胱天冬酶-1和GSDMD)。
我们的实验数据显示,秋水仙碱治疗可显著减轻心肌损伤和纤维化,同时改善心脏功能(P < 0.05)。机制上,秋水仙碱给药减少了促炎细胞因子的释放(IL-1β和IL-18),减少了中性粒细胞浸润,并抑制了心肌细胞焦亡。这些心脏保护作用与ESR1-PI3K-Akt-NF-κB信号通路的调节有关(P < 0.05),提示秋水仙碱在心肌保护中的潜在治疗机制。
秋水仙碱通过ESR1-PI3K-Akt-NF-κB信号通路抑制心肌梗死后的心肌焦亡并减少心肌细胞损伤。